Adoption of decentralized clinical trials (DCTs) and other alternatives to conventional clinical trials accelerated in response to the challenges created by Covid-19. Keeping clinical trials on track in the midst of lockdowns and the added strain on the healthcare system encouraged drug development companies to implement new tools to help educate patients about participating in clinical trials, obtain consent, collect patient data, monitor patient compliance, and manage clinical supplies.
In this podcast, Mark Maietta, president of YPrime, talks about examples of technologies that can enable DCTs as well as some challenges sponsors face when implementing technologies for DCTs. He discusses:
- Factors that have influenced the move toward DCTs
- Importance of adapting DCT strategies to specific therapeutic areas or indications
- Considerations when designing a DCT strategy
- Questions sponsors should ask themselves and their technology partners
